For years, scientists have searched for ways to trigger the body's own defenses against cancer and other diseases associated with abnormal immunity. This search has led to the discovery of a number of important new biological and chemical substances that augment, direct or restore many of the normal defenses of the body. These substances are in essence the natural drugs of the body that endow us with immunity and resistance to disease.
Now called biological response modifiers (BRMs), most of these 'lsnew medicines’, such as thymosins, lymphokines, and interferons, occur naturally in the body, while others, synthetic immunomodulators and thymomimetic agents (drugs that mimic thymic function) have been created in the laboratory. Previously, therapeutic drug development in this area relied upon chemical synthesis or introduction of bacterial adjuvants, or modified viral compounds and substances, which were foreign to the body. Therefore, they did not and do not rely upon or use the body's natural immune and biological response systems for protection against disease, function and response to the environment.
Although scientists have known about BRMs for years, isolating and purifying them so that they could be used to treat diseases has been extremely difficult. Many of these substances, such as the lymphokines, occur in the body in minute amounts and normally do not circulate in the blood. The development of new technologies for isolation and large scale synthesis, e.g. solid phase peptide synthesis, high-pressure liquid chromatography microsequencing and genetic engineering, has now permitted scientists to isolate, purify, and synthesize BRMs in sufficiently large quantities to allow human clinical trials. In this paper we will focus on the potential clinical applications of the thymosins and anti-thymosins.
Thymus Thymosins Neuroendocrine Cancer Aging AIDS
This is a preview of subscription content, log in to check access.
Hall N R, McGillis J P, Spangelo B L, Goldstein A L: Evidence that thymosins and other biologic response modifiers can function as neuroactive immunotransmitters.J Immun135 (Suppl 2), 806s (1985).Google Scholar
Goldstein A L (ed):Thymic Hormones and Lymphokines: Their Chemistry and Clinical Applications. New York, Plenum Press, (1984).Google Scholar
Haritos A A, Goodall G J, Horecker B L: Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.Proc Natl Acad Sci USA81, 1008 (1984).PubMedCrossRefGoogle Scholar
Goldstein A L, Slater F D, White A: Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin).Proc Natl Acad Sci USA56, 1010 (1966).PubMedCrossRefGoogle Scholar
Hooper J A, McDaniel M C, Thurman G B, Cohen G H, Schulof R S, Goldstein A L: Purification and properties of bovine thymosin.Ann NY Acad Sci249, 125 (1975).PubMedCrossRefGoogle Scholar
Zatz Met al: InBiological Responses to Cancer, pp. 219–247. Plenum Press (1982).Google Scholar
Huang K Y, Kind P D, Jagoda E M, Goldstein A L: Thymosin treatment modulates production of interferon.J Interferon Res1, 411 (1981).PubMedGoogle Scholar
Ishitsuka H, Yagi Y: InThymic Hormones and Lymphokines, pp. 425–438. New York, Academic Press (1984).Google Scholar
Goldstein A L, Low T L, McAdoo M, McClure J, Thurman G B, Rossio J, Lai C Y, Chang D, Wang S S, Harvey C, Ramel A H, Meienhofer J: Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide.Proc Natl Acad Sci USA74, 725 (1977).PubMedCrossRefGoogle Scholar
Caldarella J, Goodall G J, Felix A M, Heimer E P, Salvin S B, Horecker B L: Thymosin alpha 11: a peptide related to thymosin alpha 1 isolated from calf thymosin fraction 5.Proc Natl Acad Sci USA80, 7424 (1983).PubMedCrossRefGoogle Scholar
Low T L, Hu S K, Goldstein A L: Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.Proc Natl Acad Sci USA78, 1162 (1981).PubMedCrossRefGoogle Scholar
Hannappel E, Davoust S, Horecker B L: Thymosins beta 8 and beta 9: two new peptides isolated from calf thymus homologous to thymosin beta 4.Proc Natl Acad Sci USA75, 1708 (1982).CrossRefGoogle Scholar
Erickson-Viitanen S, Ruggieri S, Natalini P, Horecker B L: Thymosin beta 10, a new analog of thymosin beta 4 in mammalian tissues.Arch Biochem Biophys225, 407 (1983).PubMedCrossRefGoogle Scholar
Ruggieri S, Erickson-Viitanen S, Horecker B L: Thymosin beta arg10, a major variant of thymosin beta 10 in rabbit tissues.Arch Biochem Biophys226, 388 (1983).PubMedCrossRefGoogle Scholar
Wara D W, Martin N L, Wara W M, Goldstein A L, McClure J E: Thymosin α1 levels in children with primary cellular immunodeficiency and in adults with malignancy; in Serrou,Current Concepts in Human Immunology and Cancer Immunomodulation. New York, Elsevier Biomedical Press (1982).Google Scholar
Wara D W, Goldstein A L, Doyle N E, Ammann A J: Thymosin activity in patients with cellular immunodeficiency,New Engl J Med292, 70 (1975).PubMedGoogle Scholar
Ohta Y, Tezuka E, Tamura S, Yagi Y: Thymosin alpha 1 exerts protective effect against the 5-FU induced bone marrow toxicity.Int J Immunopharmac7, 761 (1985).CrossRefGoogle Scholar
Talmadge J E, Uithoven K A, Lenz B F, Chirigos M: Immunomodulation and therapeutic characterization of thymosin fraction five.Cancer Immun Immunother18, 185 (1984).Google Scholar
Schulof R S, Lloyd M J, Cleary P A, Palaszynski S R, Mai D A, Cow J W Jr, Alabaster O, Goldstein A L: A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer.J Biol Response Modif4, 147 (1985).Google Scholar
Lavastida M T, Goldstein A L, Daniels J C: Thymosin administration in autoimmune disorders.Thymus2, 287 (1981).PubMedGoogle Scholar
Jacobs R Pet al: InProceedings Thymic Hormone Therapy, Vol. 16, pp. 267–276. New York, Raven Press (1985).Google Scholar
Naylor P H, Goldstein A L: The thymus-AIDS connection.Bioassays1, 64 (1984).Google Scholar
Goldstein, A L, Naylor P H, Schulof R S, Simon G L, Sztein M B, Kessler C M, Robert-Gunoff M, Gallo R C: Thymosin in the staging and treatment of HLTV-III positive homosexuals and hemophilliacs with AIDS-related immune dysfunction, inAIDS-Associated Syndromes, pp. 125–140. New York, Plenum Press.Google Scholar
Frasca D, Adorini L, Doria G: Enhancement of helper and suppressor T cell activities by thymosin alpha 1 injection in old mice.Immunopharmacology10, 41 (1985).PubMedCrossRefGoogle Scholar
Ershler W B, Moore A L, Hacker M P, Ninomiya J, Naylor P, Goldstein A L: Specific antibody synthesisin vitro. II. Age-associated thymosin enhancement of antitetanus antibody synthesis.Immunopharmacology8, 69 (1984).PubMedCrossRefGoogle Scholar
Hall N R, Goldstein A L: The thymus-brain connection: interactions between thymosin and the neuroendocrine system.Lymphokine Res2, 1 (1983).PubMedGoogle Scholar
Rebar R W, Miyake A, Low T L, Goldstein A L: Thymosin stimulates secretion of luteinizing hormone-releasing factor.Science214, 669 (1981).PubMedCrossRefGoogle Scholar
Healy D L, Hodgen G D, Schulte H M, Chrousos G P, Loriaux D L, Hall N R, Goldstein A L: The thymus-adrenal connection: thymosin has corticotropin-releasing activity in primates.Science222, 1353 (1983).PubMedCrossRefGoogle Scholar